Clinical parameters affecting survival outcomes in patients with low-grade serous ovarian carcinoma: an international multicentre analysis.
May T, Bernardini M, Lheureux S, Aben KKH, Bandera EV, Beckmann MW, Benitez J, Berchuck A, Bjørge L, Carney ME, Cramer DW, deFazio A, Dörk T, Eccles DM, Friedlander M, García MJ, Goode EL, Hein A, Høgdall CK, Jensen A, Johnatty S, Kennedy CJ, Kiemeney LA, Kjær SK, Kupryjańczyk J, Matsuo K, McGuire V, Modugno F, Paddock LE, Pejovic T, Phelan CM, Riggan MJ, Rodriguez-Antona C, Rothstein JH, Sieh W, Song H, Terry KL, van Altena AM, Vanderstichele A, Vergote I, Thomsen LCV, Webb PM, Wentzensen N, Wilkens LR, Ziogas A, Jiang H, Tone A; Ovarian Cancer Association and the Australian Ovarian Cancer Study Group.
May T, et al.
Can J Surg. 2023 Jun 27;66(3):E310-E320. doi: 10.1503/cjs.017020. Print 2023 May-Jun.
Can J Surg. 2023.
PMID: 37369443
Free PMC article.
Of the 659 patients with International Federation of Obstetrics and Gynecology stage data, 156 (23.7%) had stage I disease, 64 (9.7%) had stage II, 395 (59.9%) had stage III, and 44 (6.7%) had stage IV. Of the 377 patients with surgical data, 200 (53.0%) had no visible res …
Of the 659 patients with International Federation of Obstetrics and Gynecology stage data, 156 (23.7%) had stage I disease, 64 (9.7%) had st …